CK #

Related by string. CK# [001] * CKD . ck . CKS . Ck : f * ck . f * cking [002] . F * ck . CK Cooper / # [012] . # [007] . # [016] . #s [002] : #.# ov #-# . ID # # . #-#:# pm [001] . i Newswire #-#-# * evaluating CK # . CK # novel . commercialize CK # . CK # skeletal muscle . CK # plasma . Activator CK # . CK # administered . CK # selectively . CK # plasma concentrations . CK # exercisable . intravenous CK # *

Related by context. Frequent words. (Click for all words.) 64 pharmacodynamic 63 RDEA# 60 PRX # 60 pharmacokinetics 59 Phase Ib 57 XL# [003] 57 pharmacokinetic 57 dose escalation 57 preclinical studies 56 perifosine 56 Phase 1b 56 RG# [001] 56 APD# 56 pharmacodynamics 56 investigational drug 56 CYT# 55 INCB# [002] 55 Phase 2b study 55 preclinical 55 dose escalation study 55 pharmacokinetic profile 55 Phase IIa 55 MB# [004] 54 tolerability 54 Locteron 54 Cytokinetics 54 Phase 2b clinical 54 Phase III clinical 54 arimoclomol 54 MGCD# [002] 54 Phase 2a 54 Phase IIa clinical 53 elesclomol 53 ANA# 53 Hematide 53 ADX# 53 sitagliptin 53 Phase IIb clinical 52 orally administered 52 pivotal Phase III 52 Phase 2a clinical 52 placebo controlled 52 CUDC 52 MDV# 52 safety tolerability 52 oral dosing 52 Riquent 52 laquinimod 52 FOLOTYN 51 ARRY 51 renal function 51 mg dose 51 carfilzomib 51 neuroprotective 51 Tovaxin 51 Phase IIb 51 mipomersen 50 AEOL # 50 plasma concentrations 50 satraplatin 50 SPP# [001] 50 clinically meaningful 50 AEZS 50 AZD# 50 ALKS 50 picoplatin 50 immunogenicity 50 Phase 2b 50 primary endpoint 49 PMX # 49 ITMN 49 TMC# [001] 49 pivotal Phase 49 solid tumors 49 blind placebo controlled 49 investigational compound 49 etanercept 49 hematological malignancies 49 Genasense 49 evaluable 49 humanized monoclonal antibody 49 Stimuvax 49 Phase III 49 clinical trial 49 NKTR 49 sunitinib 49 Phase III clinical trials 48 PLX# 48 tolerability profile 48 antitumor activity 48 bavituximab 48 disease modifying 48 double blind placebo 48 dosing regimens 48 naproxcinod 48 PBT2 48 preclinical models 48 alemtuzumab 48 sirolimus 48 ENMD 48 pharmacologic

Back to home page